ReviewCurrent oncology reports2020
Management of the Small Renal Mass: a 2020 Update.
Review in Current oncology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic value of percutaneous sampling in Bosniak III-IV renal cysts: a systematic review and meta-analysis.The Canadian journal of urology · 2026Pooled it
- Added diagnostic value of pseudocapsule and ADC heterogeneity beyond ccLS v2.0 in small renal masses.Abdominal radiology (New York) · 2026Article
- Review
- A simple method based on qualitative MRI features for characterizing clear cell renal cell carcinoma in small renal masses: comparison with the clear cell likelihood score.Abdominal radiology (New York) · 2025Article
- Agreement between Routine-Dose and Lower-Dose CT with and without Deep Learning-based Denoising for Active Surveillance of Solid Small Renal Masses: A Multiobserver Study.Radiology. Imaging cancer · 2025Article
- Quo Vadis HyperpolarizedZeitschrift fur medizinische Physik · 2025Review
- Synchronous papillary renal neoplasm with reverse polarity and multilocular cystic renal neoplasm of low malignant potential in unilateral kidney: case report with molecular analysis and literature review.Frontiers in oncology · 2025Article
- Computed tomography-guided percutaneous biopsy in diagnosis of suspected metastatic renal cell carcinoma: which location is the most suitable?Wideochirurgia i inne techniki maloinwazyjne = Videosurgery and other miniinvasive techniques · 2024Article
- Clinical T1/2 renal cell carcinoma: multiparametric dynamic contrast-enhanced MRI features-based model for the prediction of individual adverse pathology.World journal of surgical oncology · 2024Article
- The Role of CT Imaging in Characterization of Small Renal Masses.Diagnostics (Basel, Switzerland) · 2023Review
- Real world outcomes of biopsy-proven oncocytic neoplasm of the kidney managed by surveillance.BJUI compass · 2022Article
- Pathological diagnostic nomograms for predicting malignant histology and unfavorable pathology in patients with endophytic renal tumor.Frontiers in oncology · 2022Article
- PEG-coated patch parenchymal closure technique and initial outcomes during minimally invasive partial nephrectomy.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2022Article
- Added Value of Systemic Inflammation Markers in Predicting Clinical Stage T1 Renal Cell Carcinoma Pathologically Upstaged to T3a.Frontiers in oncology · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewSmall renal masses (≤ cT1a, less than 4 cm) are a subset of renal tumors with low malignant and metastatic potential but increasing incidence given increased use of cross-sectional imaging. Here, we review the diagnostic and treatment options available for the lesions. RECENT
findingsWhile the low metastatic potential of SRMs has been known, recent studies show that 30% of SRMs removed surgically are benign. Renal biopsy is a tool that can be implemented to help with diagnosis before treatment (options of which include active surveillance, ablation, and surgery). Active surveillance might be associated with worse cancer-specific survival but all interventional methods appear to fare similarly. Advancements have also been made in percutaneous ablation techniques, and they now are included on multiple guideline statements. Active surveillance, surgery (PN and RN), and thermal ablation are all treatment options for SRMs with similar outcomes but varying side effects.
Indexed as
Identifiers
32514631What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.